$0.38 EPS Expected for PetIQ, Inc. (NASDAQ:PETQ) This Quarter

Brokerages predict that PetIQ, Inc. (NASDAQ:PETQGet Rating) will announce earnings per share of $0.38 for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for PetIQ’s earnings, with the highest EPS estimate coming in at $0.53 and the lowest estimate coming in at $0.32. PetIQ posted earnings per share of $0.65 during the same quarter last year, which suggests a negative year over year growth rate of 41.5%. The business is scheduled to report its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that PetIQ will report full-year earnings of $1.22 per share for the current fiscal year, with EPS estimates ranging from $1.16 to $1.29. For the next year, analysts forecast that the business will report earnings of $1.74 per share, with EPS estimates ranging from $1.34 to $2.20. Zacks’ EPS averages are a mean average based on a survey of research analysts that follow PetIQ.

PetIQ (NASDAQ:PETQGet Rating) last issued its earnings results on Wednesday, May 4th. The company reported $0.62 EPS for the quarter, beating analysts’ consensus estimates of $0.37 by $0.25. PetIQ had a positive return on equity of 10.92% and a negative net margin of 1.56%. The firm had revenue of $275.70 million for the quarter, compared to the consensus estimate of $269.45 million. During the same quarter in the previous year, the company posted $0.31 earnings per share. The business’s quarterly revenue was up 8.4% compared to the same quarter last year.

PETQ has been the topic of a number of recent research reports. Raymond James lowered their target price on PetIQ from $32.00 to $29.00 and set an “outperform” rating on the stock in a research note on Thursday, March 3rd. Truist Financial lowered their target price on PetIQ from $35.00 to $30.00 in a research note on Tuesday, March 22nd. Oppenheimer downgraded PetIQ from an “outperform” rating to a “market perform” rating in a research note on Friday. Finally, Zacks Investment Research upgraded PetIQ from a “strong sell” rating to a “hold” rating in a research note on Wednesday, May 4th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $29.20.

Several institutional investors and hedge funds have recently added to or reduced their stakes in PETQ. Moors & Cabot Inc. bought a new stake in shares of PetIQ during the 3rd quarter worth about $27,000. Byrne Asset Management LLC acquired a new position in shares of PetIQ during the 4th quarter worth about $28,000. Allspring Global Investments Holdings LLC acquired a new position in shares of PetIQ during the 4th quarter worth about $31,000. Sageworth Trust Co of South Dakota acquired a new position in shares of PetIQ during the 4th quarter worth about $37,000. Finally, BNP Paribas Arbitrage SA lifted its position in shares of PetIQ by 433.2% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 4,847 shares of the company’s stock worth $121,000 after purchasing an additional 3,938 shares during the last quarter. Institutional investors own 97.45% of the company’s stock.

Shares of NASDAQ PETQ opened at $16.13 on Tuesday. The business’s 50-day moving average price is $21.83 and its two-hundred day moving average price is $21.58. The company has a debt-to-equity ratio of 1.82, a current ratio of 2.35 and a quick ratio of 1.39. PetIQ has a one year low of $14.65 and a one year high of $42.10. The company has a market capitalization of $474.38 million, a P/E ratio of -31.63, a price-to-earnings-growth ratio of 0.80 and a beta of 1.55.

PetIQ Company Profile (Get Rating)

PetIQ, Inc operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which include flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as distributes third-party branded medications.

Featured Stories

Get a free copy of the Zacks research report on PetIQ (PETQ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for PetIQ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetIQ and related companies with MarketBeat.com's FREE daily email newsletter.